On 29 Sept 2026, CHIHO ENV (00976.HK) said its indirect controlling shareholders' restructuring ended by court ruling on 20 Aug 2026; its shares stay suspended.
On 29 Sept 2026, MAANSHAN IRON (00323.HK) agreed to sell a 92% target stake to its controlling shareholder Magang Group for RMB136,306,327.57.
On 30 Sept 2026, CHI ASIA VALLEY (00063.HK) posted H1 revenue of HK$78.47m, up about 8%, and a profit of HK$3.3m; no interim dividend.
On 30 Sept 2026, S-ENJOY SERVICE (01755.HK) said its forensic investigation is complete and all results published; a resumption proposal is under review.
On 30 Sept 2026, RED AVENUE (09607.HK) said its controller ZHANG NING will buy 6.5m-13m H shares within 12 months; a first 733,400 shares bought for HK$29.4m.
On 29 September 2026, YING HAI GROUP (08668.HK) said its C U Macau unit won a Macao taxi general licence for up to 50 taxis, valid eight years.
On 29 September 2026, BEFAR GROUP (06745.HK) appointed Mr. Sun Qingwei as joint company secretary and obtained a waiver from Listing Rules 3.28 and 8.17.
On 29 September 2026, MINISO (09896.HK) said CFO Mr. Jingjing Zhang bought about HKD 2.7 million of company shares in the open market.
On 29 September 2026, TIANLI INT HLDG (01773.HK) updated the valuation of its art education target to RMB 358.62 million, up 2.8% from the original valuation.
On 29 September 2026, IDT INT'L (00167.HK) agreed to buy 40 units of AI servers for RMB 127.11 million from Hangzhou Dongnan Jitong, a discloseable transaction.
On 29 September 2026, DIRECT DRIVE (06731.HK) signed a strategic cooperation deal with China Rare Earth Group Innovation Technology.
On 29 September 2026, SIGENERGY (06656.HK) said it completed registration of its Chinese name change in Shanghai and Hong Kong; the stock code is unchanged.
On 29 September 2026, TOP FORM INT'L (00333.HK) said major shareholder Mr. Wong will lend up to USD 3 million to its unit TFB for 24 months at SOFR plus 2.0%.
On 29 September 2026, LIVZON PHARMA (01513.HK) said its Leuprorelin Acetate Microspheres for Injection 11.25mg was approved for marketing in China.
On 29 September 2026, CSPC PHARMA (01093.HK) said the Phase Ib trial of JMT206 Injection for weight management in overweight or obese adults began in China.
On 29 September 2026, JIUTAI DIGITAL (06918.HK) said it issued HKD 21m convertible bonds at an initial conversion price of HKD 0.120084154975807 per share.
